The clinical efficacy of fluticasone propionate combined with ACEIARB in the treatment of IgAN

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200060932

Enrollment

Unknown

Registered

2022-06-14

Start date

2022-06-01

Completion date

Unknown

Last updated

2023-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IgAN

Interventions

treatment group: Fluticasone propionate inhalation aerosol (250µg Bid) on the Basic treatment of ACEI/ARB

control group :Basic treatment of ACEI/ARB

Eligibility

Sex/Gender

All

Age

18 Years to 55 Years

Inclusion criteria

Inclusion criteria: (1) Age range is between 18 and 55; (2) Blood pressure is kept below 130/90 mmHg after 3-month treatment of maximum tolerable dose of ACEI/ARB; (3) eGFR calculated by using CKD-EPI formula is no less than 45ml/mim/1.73m2; (4) The quantity of the urinary protein =1.0 g/d or ACR =0.8g/g twice in a row.

Exclusion criteria

Exclusion criteria: (1) secondary IgAN; (2) using corticosteroid or immunosuppressive agents within the year before treatment; (3) having a history of allergies to ACEI and or ARB; (4) Albumin 5.5mmol/L; (7) Acute respiratory infections; (8) Unilateral or bilateral renal artery stenosis; (9) women who are pregnant or nursing; (10) Serious heart, brain, liver or hematopoietic system disorders or other nasty diseases influencing the survival; (11) Engaged in other clinical researches.

Design outcomes

Primary

Measure	Time frame
UACR;SCr;Daily urinary protein;	—

Secondary

Measure	Time frame
blood pressure;blood lipid;BMI;	—

Countries

China

Contacts

Public ContactSun Liping

slp08@126.com13428938691

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026